Last reviewed · How we verify

NCT07497308: LVAD-GDF15

GDF-15 and Early Outcomes After LVAD Implantation

Recruiting now Last updated 27 March 2026
What this trial tests

trial in Advanced Heart Failure in 48 participants. Currently enrolling.

Timeline
4 February 2026
Primary endpoint
10 August 2026
23 December 2026

Quick facts

Lead sponsorAkdeniz University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment48
Start date4 February 2026
Primary completion10 August 2026
Estimated completion23 December 2026
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Akdeniz University

Who can join

18 and older, any sex, with Advanced Heart Failure or Left Ventricular Assist Device Implantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational study aims to investigate the association between preoperative GDF-15 levels and early postoperative outcomes in patients undergoing left ventricular assist device (LVAD) implantation. The study will evaluate whether elevated preoperative GDF-15 levels are associated with adverse early outcomes, including postoperative complications and mortality. The findings may help improve preoperative risk assessment and identify high-risk patients before LVAD implantation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Akdeniz University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07497308.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing